Curaleaf Demands Engagement From Aurora Amid Fierce Acquisition Dispute
Curaleaf condemns Aurora Cannabis for rejecting its enhanced proposal, accusing the board of obstructing engagement and fair value.
Stocks · News reference
Filed: 2026-11-05 AccNo: 0001628280-26-070782 Size: 921 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Curaleaf condemns Aurora Cannabis for rejecting its enhanced proposal, accusing the board of obstructing engagement and fair value.
Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (NASDAQ:ACB), the Canadian-based leading global medical cannabis company, today reconfirms that the Board of Directors (the "Board"), on
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global medical cannabis company, responded today to a press release issued by Curaleaf Holdings, Inc.
In a letter released today, Chairman and CEO Boris Jordan encouraged Aurora shareholders to review the facts and carefully consider the alternatives available to them.Curaleaf Holdings, Inc. Logo"Aurora shareholders